The subject has received cytotoxic chemotherapy (including investigational cytotoxic chemotherapy) or biologic agents (eg, cytokines or antibodies) within  weeks, or nitrosoureas/mitomycin C within  weeks before the first dose of study treatment
Patients who have had chemotherapy (including investigational cytotoxic chemotherapy), biologic agents (e.g., cytokines or antibodies) within  weeks ( weeks for nitrosoureas or mitomycin C) before the first dose of study treatment
The subject has received cytotoxic chemotherapy (including investigational cytotoxic chemotherapy) or biologic agents (e.g., cytokines or antibodies) within  weeks, or intravesical Bacillus Calmette-Guerin (BCG) within  weeks of the first dose of study treatment
Received cytotoxic chemotherapy, radiation therapy, or targeted therapy (including investigational cytotoxic chemotherapy) or biologic agents (e.g., cytokines or antibodies) within  days of study enrollment.
The subject has received cytotoxic chemotherapy or biologic agents (e.g., cytokines or antibodies) within  days, or nitrosoureas/mitomycin C within  weeks before the first dose of study treatment
Patients who have had chemotherapy (including investigational cytotoxic chemotherapy), biologic agents (e.g. targeted therapy or antibodies) or radiotherapy within  weeks prior to the first dose of study treatment
The patient has received cytotoxic chemotherapy (including investigational cytotoxic chemotherapy) within  weeks or biologic agents (e.g., cytokines or antibodies) within  weeks prior to study enrollment
The subject has received cytotoxic chemotherapy (including investigational cytotoxic chemotherapy) or biologic agents (e.g., cytokines or antibodies) within  weeks, or nitrosoureas/mitomycin C within  weeks before the first dose of study treatment
Received cytotoxic chemotherapy (including investigational cytotoxic chemotherapy) or biologic agents (eg, cytokines or antibodies) within  weeks, or nitrosoureas/mitomycin C within  weeks before the first dose of study treatment
The subject has received cytotoxic chemotherapy (including investigational cytotoxic chemotherapy) or biologic agents (e.g., cytokines or antibodies; including investigational biologic agents) within  weeks, or nitrosoureas/ mitomycin C within  weeks before the first dose of study treatment
The subject has received cytotoxic chemotherapy (including investigational cytotoxic chemotherapy), biologic agents (e.g. cytokines or antibodies) within  weeks, or any other anti-cancer systemic therapy (including multi-kinase inhibitors)
The subject has received cytotoxic chemotherapy (including investigational cytotoxic chemotherapy) or biologic agents (eg, cytokines or antibodies) within  weeks, or nitrosoureas/mitomycin C within  weeks before the first dose of study treatment
Patients who have had chemotherapy (including investigational cytotoxic chemotherapy), biologic agents (e.g., cytokines or antibodies) or radiotherapy within  weeks ( weeks for nitrosoureas or mitomycin C) before the first dose of study treatment or those who have not recovered from adverse events due to agents administered more than  weeks earlier
No cytotoxic chemotherapy including investigational cytotoxic chemotherapy or biologic agents (e.g., cytokines or antibodies) within the last  weeks, or nitrosoureas/mitomycin C within  weeks before the first dose of study treatment; at least  weeks must have elapsed if the last regimen included an anti-cytotoxic T-lymphocyte antigen  (CTLA) antibody; patients must have experienced disease progression on their prior therapy in the opinion of the treating investigator
Cytotoxic chemotherapy (including investigational cytotoxic chemotherapy) or biologic agents (e.g., cytokines or antibodies) within  weeks, or nitrosoureas/mitomycin C within  weeks before the first dose of study treatment
Prior treatment with other anti-cancer therapies including cytokines, monoclonal antibodies, immunotherapies, and cytotoxic chemotherapy is allowed
The subject has received cytotoxic chemotherapy (including investigational cytotoxic chemotherapy) or biologic agents (eg, cytokines or antibodies) within  weeks, or nitrosoureas or mitomycin within  weeks before the first dose of study treatment
The patient has received cytotoxic chemotherapy (including investigational cytotoxic chemotherapy) or biologic agents (e.g., cytokines or antibodies) within  weeks, or nitrosoureas or mitomycin within  weeks before the first dose of study treatment
The participant has received cytotoxic chemotherapy (including investigational cytotoxic chemotherapy) or biologic agents (e.g., cytokines or antibodies) within  weeks, or nitrosoureas/ mitomycin C within  weeks before the first dose of study treatment
The subject has received cytotoxic chemotherapy (including investigational cytotoxic chemotherapy) or biologic agents (eg, cytokines or antibodies) within  weeks, or nitrosoureas/ mitomycin C within  weeks before the first dose of study treatment
The subject has received cytotoxic chemotherapy (including investigational cytotoxic chemotherapy) or biologic agents (e.g., cytokines or antibodies) within  weeks, or nitrosoureas/mitomycin C within  weeks before the first dose of study treatment
The subject has received cytotoxic chemotherapy (including investigational cytotoxic chemotherapy) or biologic agents (e.g., cytokines or antibodies) within  weeks, or nitrosoureas/mitomycin C within  weeks before the first dose of study treatment